Literature DB >> 7459177

Acute and chronic haemodynamic effects of prazosin in left ventricular failure.

L Stein, P R Foster, A W Friedman, J Statza, P L McHenry.   

Abstract

We evaluated the acute and chronic effects of prazosin treatment in 11 patients with chronic congestive heart failure, NYHA functional class III and IV. Before treatment mean arterial pressure averaged 100 +/- 15 mmHg, left ventricular filling pressure 29 +/- 11 mmHg, and systemic vascular resistance 2372 +/- 1121 dynes s cm-5. Prazosin administration resulted in haemodynamic improvement in all but one patient with significant lowering of the mean arterial pressure, left ventricular filling pressure, and systemic vascular resistance. Nine patients completed a 10-week course of ambulatory treatment. Five patients remained improved while four developed significant fluid retention; two of these had transient exacerbation of congestive heart failure. This was controlled by increasing diuretic and/or prazosin treatment. After 10 weeks all nine patients had advanced to NYHA functional class II. Repeat haemodynamic measurements disclosed complete haemodynamic tolerance in one patient while three other patients showed partial tolerance with a lower cardiac output (CO) response to prazosin. The nine patients, however, still showed significant lowering of the mean arterial pressure, left ventricular filling pressure, as well as the systemic vascular resistance. Though pharmacodynamic tolerance was noted in four out of nine patients, beneficial clinical and haemodynamic effects could be demonstrated after 10 weeks of prazosin treatment in most patients. Further evaluation of the long-term effects of prazosin in chronic congestive heart failure is warranted.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7459177      PMCID: PMC482508          DOI: 10.1136/hrt.45.2.186

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  10 in total

1.  Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography.

Authors:  N A Awan; R R Miller; A N DeMaria; K S Maxwell; A Neumann; D T Mason
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

Review 2.  Correlation of pharmacological effects with plasma levels of antihypertensive drugs in man.

Authors:  Z H Israili
Journal:  Annu Rev Pharmacol Toxicol       Date:  1979       Impact factor: 13.820

3.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

Authors:  R R Miller; N A Awan; K S Maxwell; D T Mason
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

4.  Effect of prazosin vs placebo on chronic left ventricular heart failure.

Authors:  W S Aronow; M Lurie; M Turbow; K Whittaker; S Van Camp; D Hughes
Journal:  Circulation       Date:  1979-02       Impact factor: 29.690

5.  Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure.

Authors:  M Packer; J Meller; R Gorlin; M V Herman
Journal:  Circulation       Date:  1979-03       Impact factor: 29.690

6.  Improved exercise ejection fraction with long-term prazosin therapy in patients with heart failure.

Authors:  S A Goldman; L L Johnson; E Escala; P J Cannon; M B Weiss
Journal:  Am J Med       Date:  1980-01       Impact factor: 4.965

7.  Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.

Authors:  U Elkayam; T H Lejemtel; M Mathur; H S Ribner; W H Frishman; J Strom; E H Sonnenblick
Journal:  Am J Cardiol       Date:  1979-09       Impact factor: 2.778

8.  Comparison of haemodynamic effects of oral prazosin, oral hydralazine, and intravenous nitroprusside in same patients with chronic heart failure.

Authors:  J Mehta; M Iacona; C J Pepine; C R Conti
Journal:  Br Heart J       Date:  1979-12

9.  Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.

Authors:  K Chatterjee; T A Ports; S Arnold; B Brundage; W Parmley
Journal:  Br Heart J       Date:  1979-12

10.  Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure.

Authors:  S A Rubin; K Chatterjee; H J Gelberg; T A Ports; B H Brundage; W W Parmley
Journal:  Am J Cardiol       Date:  1979-04       Impact factor: 2.778

  10 in total
  1 in total

Review 1.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.